NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-17.25 Insider Own0.30% Shs Outstand78.27M Perf Week-11.19%
Market Cap1.31B Forward P/E- EPS next Y-5.32 Insider Trans0.00% Shs Float78.14M Perf Month-26.89%
Income-1322.00M PEG- EPS next Q-1.14 Inst Own47.00% Short Float / Ratio28.90% / 4.57 Perf Quarter-52.21%
Sales1.85B P/S0.71 EPS this Y-222.50% Inst Trans5.95% Short Interest22.58M Perf Half Y-69.56%
Book/sh-7.23 P/B- EPS next Y26.40% ROA-51.30% Target Price78.17 Perf Year-92.28%
Cash/sh- P/C- EPS next 5Y58.20% ROE416.60% 52W Range16.00 - 236.50 Perf YTD-88.24%
Dividend- P/FCF- EPS past 5Y-2.50% ROI- 52W High-92.88% Beta1.81
Dividend %- Quick Ratio1.00 Sales past 5Y136.90% Gross Margin61.00% 52W Low5.19% ATR1.94
Employees1541 Current Ratio1.10 Sales Q/Q310.90% Oper. Margin-66.40% RSI (14)37.63 Volatility8.25% 10.71%
OptionableYes Debt/Eq- EPS Q/Q50.10% Profit Margin-71.60% Rel Volume1.48 Prev Close16.64
ShortableYes LT Debt/Eq- EarningsNov 08 AMC Payout- Avg Volume4.95M Price16.83
Recom2.60 SMA20-16.59% SMA50-17.33% SMA200-64.59% Volume7,248,115 Change1.14%
Sep-22-22Downgrade JP Morgan Neutral → Underweight $132 → $27
May-20-22Initiated BofA Securities Underperform $35
Feb-23-22Reiterated B. Riley Securities Buy $315 → $265
Feb-22-22Resumed Jefferies Buy $198
Jan-21-22Initiated Cowen Outperform $150
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Show Previous Ratings
Nov-29-22 01:55PM
08:48AM
Nov-28-22 12:30PM
Nov-26-22 10:37AM
05:30AM
09:00AM Loading…
Nov-25-22 09:00AM
Nov-24-22 06:00AM
Nov-23-22 12:35PM
Nov-22-22 03:46PM
01:25PM
01:11PM
09:50AM
09:45AM
09:00AM
08:11AM
05:21AM Loading…
05:21AM
Nov-21-22 06:15PM
Nov-18-22 04:02PM
12:32PM
11:40AM
08:26AM
08:08AM
Nov-15-22 06:25AM
Nov-14-22 04:02PM
09:00AM
Nov-13-22 05:21AM
Nov-10-22 05:44AM
05:06AM
Nov-09-22 04:06PM
10:46AM
10:31AM Loading…
10:31AM
09:19AM
08:25AM
Nov-08-22 07:55PM
06:08PM
05:45PM
04:58PM
04:31PM
04:31PM
04:29PM
04:21PM
04:02PM
04:02PM
01:11PM
12:33PM
11:55AM
08:11AM
08:04AM
08:00AM
08:00AM
Nov-03-22 05:50PM
Nov-01-22 08:25PM
04:30PM
04:02PM
Oct-31-22 10:00AM
Oct-28-22 06:48PM
09:00AM
Oct-27-22 10:03AM
09:53AM
Oct-26-22 05:50PM
Oct-24-22 07:07AM
Oct-21-22 06:44PM
03:25PM
Oct-20-22 02:39PM
02:15PM
01:13PM
11:28AM
11:11AM
09:37AM
06:02AM
Oct-19-22 06:43PM
05:28PM
05:13PM
04:04PM
03:23PM
12:56PM
12:05PM
11:20AM
11:03AM
10:57AM
06:00AM
Oct-18-22 05:21AM
Oct-17-22 11:09AM
09:00AM
Oct-16-22 07:02AM
Oct-15-22 08:17AM
Oct-14-22 06:55PM
12:52PM
Oct-13-22 03:48PM
10:53AM
08:46AM
08:30AM
Oct-12-22 10:50AM
10:34AM
09:35AM
09:07AM
08:57AM
08:30AM
Oct-11-22 12:15PM
Oct-10-22 11:41AM
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YOUNG JAMES FDirectorMar 31Sale73.5812,500919,76562,590Apr 04 05:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Option Exercise19.085,00095,4008,845Jan 05 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Sale140.915,000704,5343,845Jan 05 05:22 PM
YOUNG JAMES FDirectorDec 31Option Exercise25.603,75096,00078,840Jan 04 05:04 PM
YOUNG JAMES FDirectorDec 31Sale144.163,750540,60175,090Jan 04 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Option Exercise19.085,00095,4008,845Dec 22 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Sale230.005,0001,150,0003,845Dec 22 05:03 PM
Glenn Gregory MPresident, R&DDec 15Option Exercise34.821,68658,7147,349Dec 16 05:15 PM
Glenn Gregory MPresident, R&DDec 15Sale174.131,686293,5845,663Dec 16 05:15 PM
DOUGLAS RICHARDDirectorDec 13Option Exercise25.601,50038,40033,450Dec 15 05:22 PM
Glenn Gregory MPresident, R&DDec 07Option Exercise19.088,250157,41012,311Dec 09 05:20 PM
Glenn Gregory MPresident, R&DDec 07Sale170.148,2501,403,6314,061Dec 09 05:20 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Option Exercise19.085,00095,4007,760Dec 03 06:30 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Sale196.195,000980,9442,760Dec 03 06:30 PM